USE OF HEDIS A1C TARGETS IN CHARACTERIZING TREATMENT GOALS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) INITIATING BASAL INSULIN

被引：0
|
作者：
Oster, G. [1 ]
Moen, D. [2 ]
Yang, T. [3 ]
Dalal, M. [3 ]
Kazemi, M. [3 ]
Sung, J. C. [3 ]
Traylor, L. [3 ]
Sullivan, S. D. [4 ]
机构：
[1] Policy Anal Inc, Brookline, MA USA
[2] MoenMDConsulting, St Paul, MN USA
[3] Sanofi US Inc, Bridgewater, NJ USA
[4] Univ Washington, Sch Pharm, Seattle, WA 98195 USA
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 03期
关键词：
D O I：
10.1016/j.jval.2015.03.407
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB100
引用
收藏
页码：A70 / A70
页数：1
相关论文
共 50 条
  • [41] Microvascular complications in type 2 diabetes mellitus (T2DM).
    Cheung, AT
    Ramanujam, S
    Duong, PL
    Schauer, D
    Chan, LS
    Dwyre, DM
    Larkin, EC
    FASEB JOURNAL, 2002, 16 (04): : A208 - A208
  • [42] The C-Peptide Index in Korean Type 2 Diabetes Mellitus (T2DM) Patients with Oral Hypoglycemic Agents and Insulin
    Yim, Jung-Eun
    Chon, Suk
    Oh, Seungjoon
    Woo, Jeong-Taek
    Kim, Sung-Woon
    Kim, Jin-Woo
    Kim, Young-Seol
    DIABETES, 2010, 59 : A572 - A572
  • [43] Diabetic Gastroparesis: Comparison of Clinical Features in Patients with Type 2 (T2DM) and Type 1 (T1DM) Diabetes Mellitus
    Koch, Kenneth
    Hasler, William
    Calles, Jorge
    Parkman, Henry
    Pasricha, Pankaj
    Abell, Thomas
    Snape, William
    Colvin, Ryan
    Tonascia, James
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2009, 104 : S56 - S56
  • [44] THE COST-EFFECTIVENESS OF DAPAGLIFLOZIN IN COMBINATION WITH INSULIN FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN SPAIN
    Sanchez-Covisa, J.
    Capel, M.
    Schmidt, R.
    Charokopou, M.
    Verheggen, B. G.
    VALUE IN HEALTH, 2014, 17 (07) : A350 - A350
  • [45] Vildagliptin as add-on to insulin in patients with type 2 diabetes (T2DM)
    Fonseca, Vivian
    Dejager, Sylvie
    Albrecht, Diego
    Shirt, Lynda
    Schweizer, Anja
    DIABETES, 2006, 55 : A111 - A111
  • [46] Electronic Data Capture in Insulin Management for Patients (pts) with Type 1 (T1DM) and Type 2 (T2DM) Diabetes Mellitus in Global Clinical Trials
    Bastyr, Edward J., III
    Chang, Anne M.
    Mou, Jiani
    Bue-Valleskey, Juliana
    Hamilton, Robert T.
    Lesniewski, Scott J.
    Zhang, Shuyu
    Prince, Melvin J.
    DIABETES, 2014, 63 : A233 - A234
  • [47] HEALTH UTILITIES ASSOCIATED WITH HYPOGLYCEMIC EVENTS IN TYPE 2 DIABETES MELLITUS (T2DM) PATIENTS RECEIVING BASAL-BOLUS INSULIN THERAPY
    Ionova, T.
    Nikitina, T.
    Kurbatova, K.
    VALUE IN HEALTH, 2015, 18 (07) : A610 - A610
  • [48] Reasons for Different Patterns of Basal Insulin Persistence after Initiation among People with Type 2 Diabetes Mellitus (T2DM)
    Peyrot, Mark
    Ivanova, Jasmina
    Zhao, Chen
    Schmerold, Luke
    King, Sarah B.
    Birnbaum, Howard
    Delozier, Amy
    Hadjiyianni, Irene
    Kabul, Samaneh
    Cao, Dachuang
    Duan, Ran
    Perez-Nieves, Magaly
    DIABETES, 2016, 65 : A202 - A202
  • [49] HOW DIFFERENT WERE THEY? A TREATMENT PATTERN ANALYSIS OF UNITED STATES PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) INITIATING INJECTABLE THERAPY
    Walker, V
    Wei, W.
    Thayer, S.
    Brekke, L.
    Crown, W.
    Grabner, M.
    Raparla, S.
    Quimbo, R.
    Cziraky, M.
    Hu, W.
    Cuddihy, R.
    VALUE IN HEALTH, 2012, 15 (07) : A493 - A493
  • [50] Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in patients with type 2 diabetes mellitus (T2DM)
    Miyazaki, Y
    Mahankali, A
    Matsuda, M
    Mahankali, S
    Cusi, K
    Mandarino, L
    Defronzo, RA
    DIABETES, 2000, 49 : A299 - A299
12345